Minerva Neurosciences (NERV) Consolidated Net Income (2013 - 2026)
Minerva Neurosciences (NERV) posted Consolidated Net Income of -$32.3 million for Q1 2026, down 466.37% on a QoQ basis from -$5.7 million in Q4 2025, and down 762.9% year-over-year from $4.9 million in Q1 2025.
Minerva Neurosciences (NERV) Consolidated Net Income (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Consolidated Net Income history runs 14 years deep, the most recent figure standing at -$32.3 million for Q1 2026.
- Quarterly Consolidated Net Income fell 762.9% year-over-year to -$32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.0 million (down 143.59% YoY) and the FY2025 annual result came in at -$113.8 million, up 2.4% from the prior year.
- Consolidated Net Income was -$32.3 million for Q1 2026 at Minerva Neurosciences, down from -$5.7 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$2.7 million in Q3 2025 and bottomed at -$103.7 million in Q4 2023.
- A 5-year average of -$18.0 million and a median of -$5.9 million in 2024 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2024 — Consolidated Net Income soared 95.83% — and 2026, when it slumped 762.9%.
- Minerva Neurosciences' Consolidated Net Income stood at -$94.9 million in 2022, then decreased by 9.27% to -$103.7 million in 2023, then surged by 95.83% to -$4.3 million in 2024, then slumped by 31.8% to -$5.7 million in 2025, then sank by 466.37% to -$32.3 million in 2026.
- Business Quant data shows NERV's Consolidated Net Income at -$32.3 million in Q1 2026, -$5.7 million in Q4 2025, and -$2.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Minerva Neurosciences | 183.94 Mn | 183.94 Mn | - | -32.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.31 Mn |
| Dec 31, 2025 | -5.71 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -3.24 Mn |
| Mar 31, 2025 | -3.74 Mn |
| Dec 31, 2024 | -4.33 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Jun 30, 2024 | -5.93 Mn |
| Mar 31, 2024 | -6.32 Mn |
| Dec 31, 2023 | -103.68 Mn |
| Sep 30, 2023 | -6.77 Mn |
| Jun 30, 2023 | -6.18 Mn |
| Mar 31, 2023 | -4.98 Mn |
| Dec 31, 2022 | -94.88 Mn |
| Sep 30, 2022 | -5.66 Mn |
| Jun 30, 2022 | -6.89 Mn |
| Mar 31, 2022 | -8.04 Mn |
| Dec 31, 2021 | -21.37 Mn |
| Sep 30, 2021 | -7.71 Mn |
| Jun 30, 2021 | -8.98 Mn |